SecBot SecBot
Insider Cluster (6 insiders) ·Filed May 15, 2026

KPTI

Karyopharm Therapeutics Inc.
BEARISH
Impact 6/10
Horizonweeks Processed6mo ago
Insider cluster: 6 insiders, $0.0M total
Actionable Insight ▼ Bearish

The insider sales are routine post-grant liquidity events and not a standalone bearish signal. However, the $400M shelf registration and going-concern warning create acute financing risk. Monitor for an ATM drawdown or equity offering in the coming weeks, which would be highly dilutive. The Phase 3 XPORT-EC-042 endometrial cancer trial enrollment completion is a binary catalyst but does not address near-term cash needs.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$7.14
T+0 close · May 15, 2026 · via day close
Latest settled
−71.57%
T+60 · $2.03
Vs SPY
−76.42%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 18 $7.14entry
  2. T+1 · 6mo ago +4.62%α +5.27% · $7.47
  3. T+5 · 6mo ago +25.63%α +24.01% · $8.97
  4. T+20 · 5mo ago +27.45%α +25.87% · $9.10
  5. T+60 · 3mo ago −71.57%α −76.42% · $2.03

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Six Karyopharm executives, including the CEO and C-suite, sold a total of $35K in open-market shares on May 14, 2026, one day after receiving equity grants and one day after the company reported Q1 2026 earnings. The sales are trivial relative to the $201M market cap (0.017%) and coincide with a $400M shelf registration filed 10 days prior, a going-concern warning, and cash runway extending only into late Q3 2026. The cluster is likely liquidity-driven following vesting/grant events rather than a coordinated bearish signal, but the broader capital structure risk is material.

Key Financial Metrics

Direction
selling
Total Value
$35.0K
Insiders
6

Key Facts

  • Six insiders sold $35K in open-market shares on May 14, 2026, representing 0.017% of market cap
  • CEO Richard Paulson sold $21K (2,203 shares at $9.50), the largest sale in the cluster
  • All six insiders received equity grants on May 13, 2026 (non-cash, $0 value), followed by sales the next day
  • Q1 2026 revenue of $35.1M (up 17% YoY) beat consensus EPS of -$1.44 by 29%, but net loss was $22.4M
  • Phase 3 SENTRY myelofibrosis trial missed its second co-primary endpoint (symptom score)
  • $400M universal shelf registration (including $100M ATM) filed May 4, representing ~200% of market cap
  • Auditor raised substantial doubt about going concern; cash runway extends only into late Q3 2026
  • RA Capital shelf registration for 8.8M shares (resale, no proceeds to company) also filed May 4

Financial Impact

Insider sales of $35K are immaterial (0.017% of $201M market cap), but the $400M shelf registration represents potential dilution of ~200% of market cap

dilutioncash runwaygoing concern

Risk Factors

  • Massive dilution from $400M shelf registration (200% of market cap) if drawn down
  • Cash runway only into late Q3 2026, likely need for dilutive financing before then
  • Phase 3 SENTRY trial missed second co-primary endpoint, raising pipeline uncertainty
  • Going-concern warning from auditor signals potential bankruptcy risk without capital infusion

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-KPTI-1778876069336

US Market Status

Market Closed · Opens in 8h 10m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 15, 2026